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Abstract
MyomiRs are muscle-specific microRNAs (miRNAs) that regulate myoblast proliferation and differentiation. Extracellular
myomiRs (ex-myomiRs) are highly enriched in the serum of Duchenne Muscular Dystrophy (DMD) patients and dystrophic
mousemodels and consequently have potential as disease biomarkers. The biological significance of miRNAs present in the
extracellular space is not currently well understood. Here we demonstrate that ex-myomiR levels are elevated in perinatal
muscle development, during the regenerative phase that follows exercise-induced myoinjury, and concomitant withmyoblast
differentiation in culture. Whereas ex-myomiRs are progressively and specifically released by differentiating human primary
myoblasts and C2C12 cultures, chemical induction of apoptosis in C2C12 cells results in indiscriminate miRNA release. The
selective release of myomiRs as a consequence of cellular differentiation argues against the idea that they are solely waste
products of muscle breakdown, and suggests they may serve a biological function in specific physiological contexts.
Ex-myomiRs in culture supernatant and serum are predominantly non-vesicular, and their release is independent of
ceramide-mediated vesicle secretion. Furthermore, ex-myomiRs levels are reduced in aged dystrophic mice, likely as a conse-
quence of chronic muscle wasting. In conclusion, we show that myomiR release accompanies periods of myogenic differenti-
ation in cell culture and in vivo. SerummyomiR abundance is therefore a function of the regenerative/degenerative status of
the muscle, overall muscle mass, and tissue expression levels. These findings have implications for the use of ex-myomiRs as
biomarkers for DMD disease progression andmonitoring response to therapy.
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Introduction
MicroRNAs (miRNAs) are a class of small (21–22nt), non-coding RNAs
which regulate gene expression at the post-transcriptional level based
on partial sequence complementarity (1). The majority of mamma-
lian mRNA transcripts are subjected to miRNA-mediated regulation,
and as such miRNAs are involved in the control of a wide variety of
physiological processes including development, proliferation, differ-
entiation, apoptosis, and myogenesis (2,3). Additionally, miRNAs
have been implicated in various pathologies including oncogenesis,
cardiovascular disease and immunological disorders (4).
Recently, miRNAs were found to be abundant and stable in
biofluids including blood serum/plasma, cerebrospinal fluid
(CSF), urine, milk, and saliva (5). Interestingly, altered profiles of
extracellular miRNA (ex-miRNA) are associated with distinct
physiological states (e.g. pregnancy (6)), and disease conditions,
including myocardial infarction (7), muscle injury (8), liver dam-
age (9), diabetes (10), and cancer (11). As a result, ex-miRNAs are
promising disease biomarkers. An additional intriguing possi-
bility is that miRNAs are selectively secreted, taken up by recipi-
ent cells and subsequently influence gene expression in a
sequence-dependent manner. Currently, the cellular machinery
that is involved in the packaging, release, and uptake of small
RNAs is not well understood. Recent studies have identified a
variety of carriers for ex-miRNAs including exosomes and
microvesicles (12,13), apoptotic bodies (14), and vesicle-free li-
poprotein (15,16) or protein complexes (17,18) that could ac-
count for their remarkable stability in the nuclease-rich
extracellular environment.
Duchenne Muscular Dystrophy (DMD) is a progressive
muscle wasting disorder that is caused by loss-of-function
mutations in the DMD locus on the X-chromosome (19). The ab-
sence of dystrophin protein destabilises the sarcolemma, lead-
ing to repeated cycles of muscle degeneration and regeneration,
accompanied by chronic inflammation and progressive fibrosis
(20). We (21,22) and others (8,23) have identified a set of miRNAs
(miR-1, miR-133 and miR-206) that are highly enriched in the
circulation of dystrophic animal models (e.g. mdx mouse and
CXMDJ dog) and DMD patients (24) compared to sera from unaf-
fected controls. Importantly, these ex-miRNAs are potential
DMD biomarkers as they are restored towards wild-type levels
in mdx mice after dystrophin restoration by exon skipping
(21–23,25). Notably, miR-1, miR-133 and miR-206 are among the
most abundant miRNA species in myocytes (compromising
more than 25% of all miRNAs) (26) and are involved in the
control of muscle homeostasis by coordinating both myoblast
proliferation and differentiation (27,28). The expression of these
miRNAs is highly specific to skeletal and cardiac muscle, and so
they are commonly referred to as myomiRs (29,30). The tissue-
specific origins of myomiRs, and the large changes in
abundance observed for extracellular myomiRs (ex-myomiRs)
in dystrophic serum (50–100 fold (21)), makes muscle an
attractive model system in which to investigate ex-miRNA
biology.
Previously we have observed an asymmetry in myomiR ex-
pression patterns between the musculature and the circulation in
mdx mice when compared to wild-type animals (21), highlighting
that the reason for the high abundance of circulating myomiRs
cannot be explained by expression changes in muscle tissue
alone. Alternatively, gross muscle breakdown and/or passive leak-
age due to dystrophic pathology-associated membrane defects
may explain the presence of ex-myomiRs in the circulation. In
this study, we show that ex-myomiRs can be selectively released
in physiological contexts including postnatal development,
following physical exercise, and during cellular differentiation.
Our findings reveal fundamental new insights into ex-miRNA biol-
ogy and have additional implications for the use of ex-myomiRs
as disease biomarkers for DMD.
Results
MyomiR release during neonatal muscle development
and growth
During the first four weeks of life, murine muscle mass in-
creases rapidly (31). Postnatal muscle development consists of a
very active phase of satellite cell proliferation and myogenic dif-
ferentiation (32,33), accompanied by upregulation of intracellu-
lar myomiRs. We hypothesised that this development process
may also result in an altered serum myomiR signature and
sought to investigate ex-myomiR abundance during the first 28
postnatal days (PND) in wild-type (C57) and dystrophic mdx
mice.
Ex-myomiRs were highly enriched in the circulation at birth
and throughout the first week of life in both genotypes before
declining until PND 14 and then rising gradually for mdx mice
from PND 21 (Figure 1A). According to two-way ANOVA
(Supplementary Material, Table S1), the level of each individual
released myomiR changed significantly with time (P-value of
the time factor P< 0.0001 for all myomiRs). Most importantly,
miR-1, miR-133a and miR-206 dynamics followed a similar pat-
tern in both mouse strains (P-value of interaction factor P> 0.05
for all myomiRs, i.e. not significant). We used the granulocyte-
specific miR-223 as a non-myomiR control miRNA since it is sta-
bly abundant in murine serum (both wild-type and mdx) and
has therefore previously been used as an endogenous control by
our group (22,34) and others (23,25). Notably, serum abundance
of miR-223 remained unchanged over the time period investi-
gated (non-significant time factor).
In parallel, we measured clinical biochemistry markers of
tissue damage that have been shown to be elevated in DMD, in-
cluding creatine kinase (CK), alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and lactate dehydrogenase
(LDH) (35). In contrast to CK and the myomiRs, analysis of LDH,
ALT and AST showed a noticeable peak at PND 21 and levels re-
mained elevated thereafter, consistent with the known onset of
dystrophic pathology in mdx mice at three weeks of age (36,37).
(Figure 1B, Supplementary Material, Table S1). Interestingly, se-
rum CK levels closely followed the pattern observed for
myomiRs (Figure 1B). These findings are consistent with obser-
vations of elevated CK in healthy new-born humans that return
to normal within the first 10 days of life (38). In summary, the
release of ex-myomiRs in asymptomatic and pre-symptomatic
mice follows a similar pattern, with a large increase in abund-
ancy during the perinatal phase which occurs in the absence of
elevated AST and ALT levels.
We further monitored Pax7 transcript levels in the tibialis
anterior (TA) muscles to confirm satellite cell proliferation
(Figure 1C). In both genotypes, Pax7 was highly abundant during
the first week of life and expression subsequently dropped to a
low baseline level at 21 PND. mdx mice exhibited a slight in-
crease in Pax7 expression at 4 weeks of age, possibly correlated
to muscle turn-over caused by the onset of pathology.
Exercise induces delayed myomiR release
Given the dynamic changes in ex-myomiR abundance during
postnatal muscle development, we were interested to further
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investigate a possible correlation between muscle regeneration
in adult mice and ex-myomiR release. Therefore, we used phys-
ical exercise to induce regeneration through low-level, body-
wide, muscle injury. Adult muscle regeneration after injury is
reminiscent of embryonic myogenesis and consists of two inter-
dependent phases (39). Initially, myofiber necrosis and inflam-
mation is observed shortly after injury. This is followed by
activation of satellite cells that initiate regeneration, remodel-
ing and functional repair. Typically, satellite cells are activated
3 days after muscle injury, fuse with myotubes after 5 days and
begin to close the injury lesion 7 days after the initial muscle
damage (40).
Here, we subjected mdx mice to 20min of downhill exercise
and harvested blood samples repeatedly, every 2-4 days until 13
days after exercise in order to determine any changes in serum
myomiR abundance that could result from either immediate
muscle injury or a delayed regenerative response (Figure 2A).
Repeated sampling via the tail vein and normalisation to day -1
bleeds for each individual mouse was employed in order to
reduce noise caused by inter-animal variability. mdx mice were
used as their serum is highly enriched for ex-myomiRs (21)
meaning that ex-myomiR detection is technically facile. To fur-
ther exacerbate exercise-mediated myoinjury, we initially sub-
jected the mice to downhill exercise, as eccentric contraction is
known to cause more muscle damage than other types of con-
tractions (41) and mdx mice have been shown to be highly sus-
ceptible to stretch-induced muscle damage (42).
Interestingly, all circulating myomiRs exhibited a dynamic
abundance pattern with an immediate increase (day 0) and a
second peak of smaller magnitude at day 7 after exercise
(Figure 2B). Importantly, this biphasic abundance pattern was
unique to the exercised group and highly similar for all
myomiRs. According to two-way ANOVA (Supplementary
Material, Table S2), ex-myomiRs abundance changed signifi-
cantly with time (P-value of time factor P< 0.05 for all
myomiRs). Furthermore, the exercised and unexercised group
behaved significantly different for miR-1 and miR-133a (P-value
of group factor P< 0.05). Similarly, post hoc analysis demon-
strated a significant increase in miR-1 abundance immediately
after exercise and a significant increase in miR-133a abundance
7 days after exercise. For all myomiRs, levels returned to the un-
exercised baseline within 4 days following the second peak.
Figure 1. Levels of ex-myomiRs are elevated in juvenile wild-type and pre-symptomatic mdx mice. Wild-type (C57) and mdx mice (n¼4-8) were sacrificed at the indi-
cated time points and blood was assayed for (A) ex-miRNA levels and (B) clinical biochemistry markers (CK, LDH, AST and ALT). Ex-myomiR and miR-223 levels were
measured by RT-qPCR using synthetic RNA standards to determine absolute copy numbers. (C) Pax7 transcript levels were determined in the TA muscle by RT-qPCR
and normalised to TATA Box Binding Protein (Tbp) expression. Values are mean þ/- SEM. Two-way ANOVA with Bonferroni post testing was performed and P-values
for interaction, group and time factors are listed in Supplementary Material, Table S1.
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Conversely, the non-myomiR control (miR-223) did not exhibit
any significant changes throughout the duration of the
experiment.
The exercise experiment was replicated in wild-type mice
although in this case no increases in ex-myomiRs were ob-
served, likely as a result of the reduced sensitivity of healthy
muscles to contraction-induced damage relative to mdx (43,44)
(Supplementary Materials, Figure S1 and Table S3). Previously,
we have shown altered miRNA release in wild-type mice imme-
diately after inducing localised myoinjury with cardiotoxin
(CTX) in the TA muscle of wild-type mice (22). Here we repro-
duced this experiment with the methodological improvements
described above (i.e. day -1 normalisation and serial measure-
ments taken over an extended time period), to additionally
monitor any delayed changes in ex-myomiR release due to
muscle regeneration following injury. Similar to our previous
findings, CTX injury caused an increase in ex-myomiRs imme-
diately after the treatment (Supplementary Materials, Figure S2
and Table S4). However, we could not detect any significant
changes at later time points, possibly because injury followed
by regeneration in a single muscle is insufficient to increase
ex-myomiRs to a detectable level beyond the initial degenera-
tive phase. Furthermore, it is important to note that myomiR
abundance in non-dystrophic mice is inherently low and close
to the limit of detection, which complicates the measurement
of relatively small changes in abundance compared to back-
ground levels.
Next, we exercisedmdx and wild-type mice with a slightly al-
tered exercise protocol without downhill incline with the aim of
decreasing the severity of the initial myoinjury and observing
whether the levels of myomiRs released immediately after exer-
cise similarly decrease (Figure 3A). Conversely, we were also in-
terested to see if the delayed increases in myomiR abundance
could still be detected with this modified exercise protocol.
Additionally, we performed end point measurements to assess
myomiR expression in skeletal muscle, and to allow for sam-
pling of larger volumes of serum and analysis of serum CK in
parallel.
CK was significantly elevated in the circulation of mdx mice
compared to wild-type as reported previously (45) (Figure 3B,
Supplementary Material, Table S5). However, CK levels after exer-
cise varied considerably across animals, consistent with other
studies (46). Interestingly, no significant increases in ex-myomiR
levels were observed immediately after treadmill running on a
level surface (Figure 3C). Therefore, serum CK levels were more
affected by exercise than were ex-myomiRs, which is in agree-
ment with previous studies (8), although only if measured imme-
diately after exercise activity. Importantly, miR-1 exhibited a
similar increase in abundance 5 days after exercise as observed
in the downhill exercise experiment (Figure 2), possibly coupled
to the regenerative phase. Likewise, miR-133a levels increased
progressively following exercise and miR-206 exhibited a very
similar pattern but failed to reach statistical significance at the
P< 0.05 level due to high inter-replicate variation. As with the
previous exercise study, we were unable to detect any changes in
ex-myomiR abundance in wild-type animals for either serum or
skeletal muscle (Figure 3, Supplementary Figure S1).
In contrast, analysis of miRNA levels in mdx TA muscle sec-
tions harvested at the same time as the serum samples showed
upregulation of miR-1 expression immediately after exercise,
but downregulation at later time points (Figure 3C). miR-206
expression was increased inmdx TA muscle relative to wild-type
animals, as described previously (21) but expression was not
altered after exercise. No changes in miR-133a were observed in
TA between wild-type and mdx, or following exercise thus high-
lighting that expression levels in tissue and abundance in serum
do not always correlate (21). To confirm that physical exercised
induced regeneration, we measured the transcript levels of myo-
sin heavy chain 3 (Mhy3) in the TAmuscle. Typically,Mhy3 is ex-
pressed during embryonic and fetal muscle development, but is
also re-expressed in regenerating fibres after injury (47). In mdx
mice Mhy3 levels were significantly increased 7 days after exer-
cise (Figure 3C) whereas we were unable to detect the transcript
in wild-type muscle at any time point, thus confirming that the
exercise regimen was insufficient to induce regeneration in non-
dystrophic mice. In summary, serum myomiRs in dystrophic
mdx mice exhibit dynamic changes in abundance depending on
the mode of exercise, possibly reflecting the degenerative and
regenerative status of the muscle.
MyomiR release is reduced in agedmdxmice
The natural process of muscle loss during aging is exacerbated in
mdxmice due to repeated cycles of degeneration and regeneration
that follow as a consequence of dystrophin-deficiency (48). In par-
ticular, at 72 weeks of age, the hind limb muscles of mdx mice
were shown to decrease in muscle mass by more than 50% in TA,
Figure 2. Acute eccentric exercise induces a biphasic abundance pattern of
myomiR release in mdx mice. (A) 12 week old male mdx mice (n¼8) were exer-
cised by running downhill for 20min at increasing speed on a treadmill with a
15˚ incline and compared with unexercised controls (n¼5). Blood was collected
at indicated time points by serially sampling from each mouse. (B) Levels of
miRNAs in serum were determined by RT-qPCR. Expression of myomiRs was
normalised to the day -1 bleed for each individual animal respectively to mini-
mise noise due to inter-animal variability. All values are mean þ/- SEM. *P<0.05
(Two-way ANOVA, Bonferroni post test). P-values for interaction, group and
time factors are listed in Supplementary Material, Table S2.
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extensor digitorum longus, soleus, and plantaris, and by up to 70%
in quadriceps and gastrocnemius, compared to age-matched wild-
type mice (49). Here, we were motivated to determine whether
chronic muscle-wasting in aged mdx mice is reflected in serum
myomiR abundance. To this end, we compared the levels of
myomiRs and clinical chemistry biomarkers in the circulation of
adult (14 weeks) and aged (88 weeks)mdx and wild-type animals.
Consistent with previous data, both ex-myomiR levels and
clinical biochemistry markers of tissue injury were significantly
increased in adult mdx compared to adult wild-type mice (21,35)
(Figure 4 and Supplementary Material, Table S6). Ex-myomiRs
exhibited larger fold changes at 14 weeks (ranging from 13- to 42-
fold) than CK, LDH, ALT and AST (ranging from 2- to 9-fold).
Conversely, neither the ex-myomiRs nor clinical biochemistry
serummarkers were significantly different between genotypes in
aged mice. Ex-myomiR abundance was restored to near wild-
type levels in the aged mice, likely as a result of aging-associated
muscle loss. In agreement, the body weight of aged mdx mice
was significantly decreased compared to aged wild-type mice
(Supplementary Material, Figure S3A). Furthermore, Hematoxylin
and Eosin staining of the quadriceps femoris muscles demon-
strated severely advanced pathology in aged dystrophic mice
with extensive fibrosis and adipose deposition (Supplementary
Material, Figure S3B. Serum myomiR levels in aged wild-type
mice were not significantly altered compared to adult non-
dystrophic animals. Notably, levels of the non-myomiR control
miR-223 were unaffected by age or dystrophic pathology. Given
their muscle-specific origins, these data suggest that serum
myomiR abundance is also correlated to muscle mass in addition
to reflecting the regenerative/degenerative status of muscle.
Progressive myomiR release during myogenic
differentiation
Given that myogenic differentiation is accompanied by in-
creased expression of cellular myomiRs, we were interested to
investigate whether intracellular myomiR induction in muscle
cell cultures is correlated with an elevated release of muscle-
Figure 3. End point analysis of miRNAs and CK in serum and tissue after exercise. (A) 12-week-old malemdx and wild-type (C57) mice were exercised for 20min by run-
ning on a level surface at increasing speed. Animals were sacrificed at the indicated end points (n¼3) and tissue samples and serum harvested. (B) CK was measured in
mdx and wild-type serum. Levels of miRNAs in (C) serum or muscle of mdx and wild-type (D and Supplementary Material, Figure S1) were determined by RT-qPCR.
Myh3 transcript levels were measured by RT-qPCR and normalised to TATA Box Binding Protein (Tbp) expression. Myh3 was undetectable in wild-type mice (D). CK¼
Creatine Kinase, WT¼ wild-type, C¼ not exercised control animals. All values are mean þ SEM. *P<0.05, **P<0.01, ***P<0.001 (Two-way ANOVA with Bonferroni post
test (B) (P-values are listed in Supplementary Material, Table S5) and one-way ANOVA with Bonferroni post test (C,D).
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specific miRNAs, reminiscent of the myomiR release we ob-
served in vivo during muscle development and regeneration.
Firstly, primary human myoblasts were differentiated into mul-
tinucleated myotubes over the course of 9 days. RNA was iso-
lated from cells and conditioned media collected every 3 days.
The medium was replaced at regular intervals so that each su-
pernatant sample represents the quantity of released miRNAs
over the 3day period and not the accumulation of secreted
miRNA over the entire duration of differentiation (Figure 5A).
Myotube formation was confirmed by light microscopy and
quantification of transcripts of the myogenic regulatory factors
MYOD1 andMYOG (Supplementary Material, Figure S4).
Cellular expression of myomiRs was strongly and progres-
sively induced with a 100-1000 fold increase in expression after
9 days of differentiation (Figure 5B). Absolute intracellular
myomiR copy numbers after 9 days of differentiation reached
similar levels of 100 million copies/mg RNA with miR-206
and miR-1 being the most abundant species measured.
Concurrently, myogenic differentiation was associated with a
strong, progressive increase (up to 100 fold) in the release of
myomiRs, especially at the later stages of differentiation where
multinucleated myotubes were visible (Supplementary Material,
Figure S4C). Despite slightly differing patterns of release, after 9
days the absolute levels of myomiRs in the media were similar
for miR-206 (0.4 million copies/ml) and miR-133a (0.2 million
copies/ml) and somewhat lower for miR-1 (0.04 million copies/
ml). Notably, cellular miRNA and secreted ex-miRNA levels were
positively correlated for all myomiRs (Pearson coefficients: 0.
7809 (miR-1), 0.7515 (miR-133a), 0.8219 (miR-206); all P< 0.01,
Supplementary Material, Table S7). Three additional non-
myomiR control miRNAs were measured in parallel: miR-16
(ubiquitously expressed, previously used for miRNA normalisa-
tion in tissues (21,50)), let-7a (highly abundant in muscle tissues
(51)), miR-31 (involved in regulating muscle processes (52) and
recently proposed as a reference miRNA in serum (53)). All three
control miRNAs exhibited relatively stable expression in cells,
and stable abundance in cell culture supernatant over the course
of the experiment (Figure 5B). Conversely, there was no signifi-
cant correlation between cellular and secreted miRNA levels for
these three non-myomiR controls. Importantly, let-7a was
highly abundant (1.5 billion copies/mg RNA) in muscle cells
throughout the period of differentiation. Considering this high-
intracellular abundancy, let-7a was found at comparatively low
levels in the supernatant (0.1 million copies/ml), thus highlight-
ing the selectivity of myomiR release.
As primary muscle cells are of limited availability and are
difficult to culture for extended periods of time, we were inter-
ested to see if these findings could be recapitulated in an
immortalised myoblast cell line (C2C12). Upon serum depletion,
C2C12 cells differentiated to form multinucleated myotubes
with a concomitant induction of cellular myomiR expression
(Figure 5C). Myogenic differentiation was visualised by immu-
nostaining for Myosin Heavy Chain (MHC)-positive myotubes,
which became apparent three days in differentiation condi-
tions, and continued to mature into larger myotubes
(Supplementary Material, Figure S4D). Importantly, myogenic
differentiation progressively induced myomiR release up to
100 fold after 9 days of differentiation. As with the primary hu-
man myoblasts, cellular and secreted levels of myomiRs in
C2C12 cells were likewise strongly correlated (Pearson coeffi-
cients: 0.9291 (miR-1), 0.8878 (miR-133a), 0.8937 (miR-206); all
P< 0.0001, Supplementary Material, Table S7) whereas the non-
myomiR controls were not correlated (miR-31 and let7-a) or had
weak correlation coefficients (miR-16). Notably, the absolute
levels of myomiRs in the media were higher in C2C12 cells than
in primary myoblast cells, probably due to higher cell density
(2.5-fold more nuclei per image section, data not shown) that
these cells achieve in culture.
Apoptosis is known to accompany normal myogenic differ-
entiation, especially during the first few days after serum with-
drawal (54). To ensure the progressive increase in ex-myomiRs
described above was not due to passive release by apoptotic
cells, cell viability was monitored throughout the course of
differentiation using a Trypan Blue dye exclusion assay
(Supplementary Material, Figure S4E). Inspection of culture
wells revealed relatively few detached cells and only a minority
of cells exhibited dye uptake. In addition, apoptosis was in-
duced in differentiated C2C12 myotubes by treatment with
Figure 4. Serum myomiRs and clinical biochemistry markers are decreased in aged mdx mice. Blood from adult (14-week old) and aged (88-week old) wild-type (C57) and
mdxmice (n¼4–5) was harvested and assayed for (A) miRNA abundance and (B) clinical biochemistry parameters. (A) SerummyomiR levels were measured using RT-qPCR
with synthetic RNA standards for absolute quantification. (B) In parallel, clinical biochemistry parameters were analysed using standard enzymatic assays. All values are
meanþSEM. **P<0.01, ***P<0.001, (Two-way ANOVA, Bonferroni post test). P-values for interaction, group and time factors are listed in Supplementary Material, Table S6.
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Staurosporine (SP) and miRNA release was measured after 24h.
Both myomiRs and non-myomiRs were highly enriched (all
P< 0.001, with the exception of miR-31 (P< 0.05)) in media from
apoptotic cultures compared to vehicle treated cultures (Figure
6A). Release of myomiRs was increased by 10–25-fold in media
after SP treatment. Non-myomiRs were similarly enriched in
apoptotic media (5–25-fold), although miR-16 and let-7a were
enriched to a lesser extent. Induction of widespread cell death
was confirmed by MTS assay (Figure 6B) and fluorescence stain-
ing for Annexin V-FITC and propidium iodide (to label early-
stage apoptosis and late-stage apoptosis/necrosis respectively)
(Figure 6C). Given the dramatic increase in the myomiR release
during normal differentiation (100–1000-fold relative to undif-
ferentiated cells) it is unlikely that the non-selective release
caused by apoptosis alone can account for ex-myomiR release
in differentiating C2C12 culture media.
In summary, both cell models demonstrate that elevated
levels of ex-myomiRs follow myogenic differentiation in
healthy, non-dystrophic myoblasts, thus supporting the idea
that ex-myomiRs are released under physiological conditions.
Additionally, our findings demonstrate that absolute expression
is not necessarily linked to the amount of miRNA release (as in
the case of let-7a), consistent with the hypothesis of a
sequence-selective mechanism of miRNA secretion. Finally, the
ability to model ex-myomiR release in C2C12 myoblast cultures
(with a homogenous cell population with sufficient capacity for
both proliferation and differentiation) will be useful for further
mechanistic studies.
Mechanism of extracellular myomiR release and
transport
Recently, a number of ex-miRNA carriers have been identified
that are capable of protecting ex-miRNAs from degradation in
the otherwise hostile, nuclease-rich environment of the blood.
Studies that have compared the number of miRNAs found in
exosomes and microvesicles (together referred to as extracellu-
lar vesicles (EVs)) with those miRNAs found outside of vesicles
have concluded that only 1–5% of circulating of ex-miRNAs are
associated with lipid-based carriers whereas the majority are
stabilised in protein-complexes (15,17,18,55). Similarly, we have
previously shown that serum myomiRs are predominantly
non-vesicular, and co-precipitate with Argonaute-2 and
Apolipoprotein-A1 (22). Importantly, the majority of studies
have used ultracentrifugation (UC) to isolate EVs, a relatively
crude methodology with significant limitations. UC has the dis-
advantage that it partly co-pellets large protein complexes, and
Figure 5. Progressive ex-myomiR release during myogenic differentiation in primary human and immortalised murine C2C12 myoblasts. Human and murine myo-
blasts were differentiated for up to 9 days in reduced serum media. (A) Cells and conditioned media were sampled as indicated. Levels of myomiR and non-myomiR
control miRNAs in (B) human primary muscle cells and (C) C2C12 cells were determined by RT-qPCR using synthetic RNA standards for absolute quantification.
Expression of cellular miRNAs was normalised to total RNA content (copies/mg RNA). The cell supernatant was sampled over 3 days periods and miRNA abundance re-
ported as copies/ml. Values are mean þ SEM, n¼3–4.
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centrifugation at high speed can cause EV aggregation, fusion
and/or rupture (56). Here, we applied an improved methodology
for EV isolation that combines ultrafiltration and size-
exclusion-chromatography (UF-SEC) which enables the isola-
tion of intact EVs with high purity and yield (57).
As we have shown that differentiating C2C12 cells are suit-
able to model miRNAs release, we used this cell line to gain in-
sight into ex-myomiR export and transport. During SEC of C2C12
cell culture supernatant, protein content was monitored by mea-
suring the absorbance at 280nm. Based on the absorbance trace
and previous data, individual eluates from the SEC were pooled
into four fractions (F1-4) (Figure 7A). Typically, EVs are contained
in fraction F1 (57) and nanoparticle tracking analysis (NTA) de-
termined the modal particle size to be 80nm in this fraction
(Figure 7B). The exosome marker proteins ALIX (PDC6IP) and
TSG101 (58) were highly enriched in fraction F1 as determined by
Western blot (Figure 7C). Together these findings confirm that
EVs within fraction F1 exhibit typical exosomal properties.
MyomiRs analysed in the pooled fractions showed a similar pat-
tern of abundance with 80% of each miRNA detected in F4 and
20% in F3. Conversely, less than 1% could be detected in the F1
fraction, thus demonstrating that ex-myomiRs are predomi-
nantly present in small protein complexes, while only a small
minority are associated with vesicles. In contrast, the non-
myomiR controls miR-16 and let-7a exhibited different distribu-
tion patterns. In particular, let-7a was also found to be abundant
in the vesicular fraction F1 (40%). These data are consistent
with previous studies in human plasma which observed let-7a
and miR-16 as exhibiting vesicular and non-vesicular
distributions, respectively (17), and therefore underline the ro-
bustness of our UF-SEC fractionationmethodology.
We next applied the UF-SEC technique to serum from mdx
mice (Figure 7E–H). Notably, we observed an early protein peak
in the 280nm absorption trace corresponding to fraction F1.
NTA analysis demonstrated that vesicles in F1 had a modal size
of 65nm. We were unable to detect exosomal protein markers
via Western blot although CD63 antigen CD63 an exosome sur-
face protein (58), was enriched in fraction F1 as determined by
ELISA (Figure 7G). MyomiR abundance was measured in each
fraction and, consistent with our cell culture findings, these
miRNAs were found to be highly abundant in the fractions with
high protein content. In contrast, 1% of myomiRs were found
in the vesicular fraction F1, thus providing further evidence that
C2C12 cultures faithfully model in vivomyomiR release.
It is currently unclear how non-vesicular ex-miRNAs can
cross the plasma membrane and be released into the extracellu-
lar space since a transmembrane export mechanism for non-
lipid-based carriers has not yet been described. One possibility
is that protein-bound miRNAs are initially packaged into vesi-
cles which are released into the extracellular space and are sub-
sequently degraded to liberate their miRNA-protein cargos.
Consequently, we used GW4869, an inhibitor of neutral sphin-
gomyelinase 2 (nSMase2) to block exosome secretion via the
ceramide pathway in differentiated C2C12 cells and then moni-
tored the effect on myomiR release. Interestingly, no significant
reduction in myomiR abundance was measured when analysing
the supernatant of GW4869-treated cells compared with DMSO-
treated or untreated cells (Figure 8A). To confirm that the
Figure 6. Induction of apoptosis in C2C12 myotubes induces indiscriminate ex-miRNA release. C2C12 cells were differentiated for 6 days and then apoptosis was in-
duced by incubation with 1 mM Staurosporine (SP) for 24h. (A) RNA was extracted from conditioned cell culture supernatants and miRNA levels were determined by
RT-qPCR. Fold changes in miRNA abundance after SP treatment are shown relative to DMSO-treated control cultures. (B) Cell viability was determined by MTS assay
and is reported as a percentage of the DMSO-treated control group. (C) Detection of apoptosis by Annexin V-FITC and Propodium Iodide (PI) fluorescence staining in
Staurosporine treated (upper panel) and control cells (lower panel). Scale bar represents 200 mm (20x magnification). Apoptosis was further assessed using Trypan Blue
staining to measure cell viability. All values are mean þSEM. *P<0.05, ***P<0.001 (unpaired t-test, 2 tailed, n¼3).
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GW4869 treatment successfully down-regulated exosome secre-
tion, we isolated EVs from C2C12 myotube conditioned media.
Notably, exosome marker proteins were decreased in exosome
preparations isolated from GW4869-treated cells by 60-80% as
demonstrated by Western blot (Figure 8B). Additionally, NTA
showed a 6 fold decrease in particle numbers after GW4869
treatment, thus confirming the successful inhibition of exo-
some secretion (Figure 8C). Given that we did not observe any
reduction in myomiR release in unfractionated conditioned me-
dia, we conclude that EV-mediated secretion is unlikely to be re-
sponsible for the majority of myomiR release.
Discussion
While muscle pathology clearly contributes to an enrichment of
muscle-specific miRNAs in the circulation, here we show that,
Figure 7. Ex-myomiRs inmyotube-conditionedmedia andmurine serum co-elute with protein complexes and are predominantly non-vesicular. 50ml of conditionedmedia col-
lected from differentiated C2C12 cells (A–D) and 1ml of pooled serum from 12-week-oldmalemdxmice (E-H) was fractionated via UF-SEC. (A) The protein contentwasmonitored
using the 280nm absorbance and eluates were pooled into 4 new fractions as indicated. (B) NTA analysis shows a modal particle size of 80nm in F1. (C) Exosomal protein
markers (ALIX and TSG101) were highly enriched in F1 as determined by Western blot analysis. (D) RNA was extracted from each pooled fraction and miRNA abundance mea-
sured by RT-qPCR. Values are depicted as the percentage distribution across all of the fractions. (E) Serumwas fractionated and divided into six different fractions as indicated in
the 280nm absorbance trace. (F) NTA analysis shows a modal vesicle size of 65nm in F1. (G) CD63 abundance was quantified using ELISA and normalised to total protein con-
centration to indicate fraction purity. (H) RNAwas extracted from each fraction andmiRNA abundancewas quantified by RT-qPCR and normalised as described above.
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the release process can also be dynamic and myomiR-specific in
various physiological contexts, including during postnatal mus-
cle development, after physical exercise, and as myoblasts dif-
ferentiate in culture. As a result, we conclude that myomiR
release accompanies periods of myogenic differentiation and
serum myomiR abundance is likely to be a function of muscle
mass and growth, degenerative/regenerative status, and tissue
expression levels.
Firstly, we monitored changes in secreted miRNA during
postnatal muscle development, a highly coordinated myogenic
differentiation process that occurs globally in all muscle groups.
In murine muscle, growth during the perinatal phase is sup-
ported by rapid accretion of new nuclei from activated satellite
cells (32). Subsequently, the rate of nuclei addition decreases in
combination with a reduction in satellite cell numbers per myo-
fibre. After 21 days, the adult level for both the number of nuclei
and satellite cells per myofibre is established, with further
growth being solely mediated by an increase in the size of the
myonuclear domain (32). In agreement with these previous
studies, we observed elevated transcript levels of the satellite
cell marker Pax7 in mdx and wild-type TA muscle during the
first 7 days of life. Subsequently, transcript levels decreased in
both genotypes and remained low from 21 PND onward.
Strikingly, we also found a strong enrichment of ex-myomiRs
during the first week of life in wild-type and pre-symptomatic
dystrophic mice (Figure 1), and thus concomitant with the high-
est rate of satellite activation and myonuclei fusion. In contrast,
myofibre growth mediated only by hypertrophy without addi-
tion of new nuclei after 21 PND (32), does not seem to be
accompanied by elevated ex-myomiR levels in wild-type mice.
Importantly, studies in 14-day-old wild-type and dystrophic
mice found no evidence of increased membrane permeability
(45), therefore arguing against the passive release of ex-
myomiRs due to defects in sarcolemma integrity at this age. We
therefore conclude that elevation of serum myomiR levels oc-
curs during periods of rapid myofibre growth and maturation,
coincident with high rates of myonuclear fusion, and most im-
portantly, in the absence of dystrophic pathology. Our findings
demonstrate that tissue-specific miRNAs can be selectively re-
leased during neonatal development.
Low level myoinjury caused by downhill exercise induced a
biphasic pattern of ex-myomiR release. This finding suggests
that myomiRs are released both during the initial myofibre de-
generation (immediately after exercise), and during subsequent
regeneration (5–7 days post exercise). In the present study, we
observed that miR-1 was the most strongly induced miRNA im-
mediately after exercise in both serum and muscle (Figure 2).
Previously, similar observations were made for miR-1 in hu-
man skeletal muscle after various types of exercise both imme-
diately following the ex ercise as well as up to 10 days later
(depending on the mode of exercise and the training status
of the individual) (59–61). Interestingly, it has been shown that
administration of exogenous miR-1, miR-133, and miR-206
oligonucleotides in rats accelerates muscle regeneration (62).
Furthermore, miR-206 is highly expressed in newly regenerated
fibres (63), is upregulated in skeletal muscle 7 days after cardio-
toxin injury, and miR-206 knockout mice exhibit delayed mus-
cle regeneration (64). Given the importance of myomiRs in
regeneration, it is possible that their specific release during
postnatal development, and after exercise, constitutes a regula-
tory signal which promotes myoblast proliferation and
differentiation.
Additionally, we monitored the abundance of serum
myomiRs during aging (Figure 4) and observed a strong decrease
in ex-myomiRs abundance in mdx mice at 88 weeks of age com-
pared with adult dystrophic mice, thus suggesting that their
abundance in the circulation declines as muscle mass is pro-
gressively lost (as is the case with serum CK which also
declines in DMD patients with advanced pathology (65)).
Importantly, the described reduction in regenerative capacity of
aged muscle (66), especially if mediated by changes in the satel-
lite cell niche, could also be related to ex-myomiR levels.
Nevertheless, these data highlight a potential complication for
the utility of serum myomiRs as biomarkers of DMD disease
progression and response to therapy. Previously, myomiRs have
been shown to be restored to wild-type levels by dystrophin
exon-skipping (21–23,25). However, our results indicate that
advanced muscle wasting could also result in return of ex-
myomiR abundance to wild-type levels on account of the de-
cline in muscle mass and/or regenerative potential. Similarly,
we show that serum myomiR abundance is also affected by
exercise. Consequently, ex-myomiR levels in patient serum
must be analysed in the context with other clinical information.
While regulation of differentiation by intracellular miRNAs
has been extensively studied, regulatory effects of secreted
miRNAs are largely unknown. Here we observed a progressive
release of myomiRs during terminal differentiation in culture.
Differentiation of myoblasts to form multinuclear myotubes in
culture has been widely applied as an in vitro model of myogen-
esis. Notably, both primary human myoblasts and C2C12 cul-
tures exhibited a similar, dynamic pattern with a strong
induction of myomiR expression and release, especially at the
advanced stages of differentiation (Figure 5). Interestingly,
Figure 8. Inhibition of exosome secretion does not affect myomiR release in C2C12
myotubes. C2C12 cells were differentiated for 4 days and treated with 10 mM
GW4869 to block exosome secretion via the ceramide pathway. (A) RNA was har-
vested from C2C12 myotube culture supernatants and miRNA levels measured by
RT-qPCR. Mean values for the untreated group were returned to 1 for each miRNA.
To confirm successful decrease in exosome secretion by the small molecule inhibi-
tor, EVs were isolated from drug- and vehicle-treated cells. (B) Particle numbers were
determined by NTA analysis in isolated EVs of GW4869 and DMSO treated cells. The
modal size was 80nm for both samples. (C) Western blot of the isolated EVs
showed a decrease in exosomal marker proteins (ALIX, TSG101 and CD9) in GW4869
treated cells compared to vehicle treated cells (DMSO). Values aremeanþ SEM.
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this pattern of myomiR release coincides with the generation
of multinucleated myocytes that express MHC as these begin
to be formed after 3 days and mature continuously by
fusing with neighbouring myotubes (Supplementary Material,
Figure S4). Importantly, this release occurred with only minimal
apoptosis and was specific to myomiRs. In contrast, chemical
induction of apoptosis in C2C12 myotubes (Figure 6) resulted
in indiscriminate ex-miRNA release, therefore highlighting
that although apoptotic cells may contribute to the pool of
released miRNAs (55), the observed dramatic increases in
ex-myomiR abundance are likely a consequence of selective re-
lease (18).
To further characterise the means by which ex-myomiRs are
protected from degradation in the extracellular space we used
UF-SEC to separate vesicles from protein-complexes. The frac-
tionation of both murine serum and conditioned media derived
from C2C12 myotube cultures demonstrated that myomiRs are
predominantly present in small protein complexes that elute
late during the fractionation process (Figure 7). Conversely, only
1% of myomiRs were associated with EVs. These observations
are consistent with our previous findings using cruder EV isola-
tion methods and differential sensitivity to Proteinase K-medi-
ated miRNA destabilisation (22). The similarities between cell
culture and in vivo results suggest that differentiating C2C12
myotubes are a useful model for the investigation of ex-
myomiR biology.
We further applied GW4869-mediated suppression of exo-
some secretion to test the hypothesis that myomiRs might be
initially exported in EVs that are subsequently broken down in
the circulation (Figure 8). However, the amount of secreted
myomiRs remained constant despite successful down-
regulation of exosome secretion. This finding argues in favour
of either a yet undescribed, non-lipid-based miRNA export pro-
cess, or direct budding of non-exosomal microvesicles from the
cell membrane that is followed by subsequent degradation of
these vesicles and liberation of protein-miRNA complexes in
the circulation. To this end, it will be important for future work
to identify the export machinery for miRNA-protein complexes.
If ex-myomiRs do in fact contribute to intracellular communica-
tion, specific receptors on recipient cells would similarly need
to be identified, as it has yet to be demonstrated that non-lipid
encapsulated miRNAs can be taken up by target cells and in-
duce sequence-specific mRNA silencing (67). Currently, there is
some limited evidence of ex-miRNAs influencing myogenesis,
but only if they are transported in EVs (68,69).
Assuming that myomiRs may participate in intracellular
communication, it will be of pivotal importance to determine
how many myomiR copies need to be transferred per recipient
cell in order to cause a measurable effect on target gene expres-
sion. In our study, we aimed to generate more meaningful data
by determining absolute copy numbers for both cellular and ex-
tracellular miRNAs rather than by simply measuring fold
changes. Previous reports state that at least 1,000 miRNA copies
per cell are necessary to induce a measurable effect on the
mRNA concentration, depending on the target mRNA turnover
rate (70,71). Notably, myomiR levels are strongly induced dur-
ing satellite cell activation and are therefore initially far less
abundant in dormant satellite cells than in myotubes (28,72).
Therefore, a plausible hypothesis is that differentiating myo-
tubes secrete myomiRs locally and thereby signal to activate
neighbouring satellite cells, thus serving to amplify the regen-
erative response in a paracrine manner. Another possible sce-
nario could be that secreted myomiRs might communicate
with other cell types in the muscle niche, such as motor
neurons or fibro-adipo progenitors to influence synapse plas-
ticity at the motor end plate or modulate the muscle extracellu-
lar milieu respectively. To this end, communication between
muscle and neuron has been demonstrated in mouse (73) and
drosophila (74), although in both cases signalling was mediated
by EVs.
In conclusion, specific increases in serum myomiR abun-
dance during periods of muscle growth, after exercise-induced
injury, and concomitant with myogenic differentiation suggest
that myomiR release is not exclusively a consequence of leak-
age from damaged or dystrophic muscle undergoing apopto-
sis/necrosis. We propose that under some circumstances the
presence of myomiRs in the serum may serve a physiological
function. Given that the great majority of ex-myomiRs appear
to be stabilised in protein complexes, future studies are re-
quired to understand the extent to which ex-myomiRs partici-
pate in intercellular communication in normal physiology, and
how they can be utilised to monitor dystrophic pathology.
Despite a plethora of studies investigating the role of miRNAs
during stem cell proliferation and progenitor cell differentia-
tion (reviewed in (75)), the influence of secreted miRNAs on
these processes is currently not well understood. While our
studies have focused on circulating miRNA as relating to
myogenesis/muscle regeneration, we propose that ex-miRNAs
release is likely to accompany alternative developmental pro-
cesses and/or cellular differentiation in other lineages, thus
comprising a general biological phenomenon that is not exclu-
sive to muscle.
Materials and Methods
Animal studies
All animal procedures were carried out in accordance with pro-
cedures authorised by the UK home office. Animals used were
male C57BL/10 (wild-type, abbreviated as C57) and C57BL/
10ScSn-Dmdmdx/J (abbreviated as mdx) mice. For the exercise
studies, mice were subjected to 20min of treadmill exercise
(Exer3/6, Columbus instruments, Columbus, OH, USA), running
with either a downward incline of 15˚, or on a level surface as
according to experimental requirements. Treadmill speed was
initially set at 5 m/min and gradually increased to 20 m/min.
Blood was collected from the tail vein for serial measure-
ments. For endpoint measurements animals were sacrificed by
escalating CO2 concentration and blood harvested from the jug-
ular vein. Animals younger than 14 days were decapitated and
blood was harvested from the corpus. In all cases, Microvette
CB300 capillary serum tubes (Sarstedt Ltd., Leicester, UK) were
used for whole blood collection. Samples were allowed to clot at
room temperature for 30min and then centrifuged at 10,000 g
for 5min. Clinical biochemistry assays were performed at the
clinical pathology laboratory, Medical Research Council Harwell
(Oxford, UK).
microRNA analysis
We have previously described our methods for the detection
and quantification of ex-miRNAs in murine biofluids in detail
(34,76). All Reverse Transcriptase quantitative Polymerase
Chain Reaction (RT-qPCR) studies were designed to comply with
the MIQE guidelines where possible. Briefly, RNA was extracted
with TRIzol LS (for biofluid samples) and TRIzol reagent (for cell
or tissue samples) according the manufacturer’s protocols (both
Life Technologies, Paisley, UK). For serum analysis, the sample
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volume used for extraction was kept constant within each study
(10ll for serial measurements, 50 ll for end point measure-
ments). Similarly, when conditioned media was analysed, equal
volumes (typically 300 ll) of cell culture supernatant were used
for RNA isolation. To monitor variation in extraction efficiencies
for biofluid samples, 3 ll of a 5 lM synthetic miRNA oligonucleo-
tide, cel-miR-39 (50-UCACCGGGUGUAAAUCAGCUUG) (IDT,
Leuven, Belgium), was added to each sample at the phenol ex-
traction stage. RNA was resuspended in 30 ll of nuclease-free
water (Life Technologies).
For miRNA quantification, either 5 ml of the RNA extracted
from serum or culture media (or 10ng of RNA if extracted from
cells/tissue) was reversed transcribed using the MicroRNA
Reverse Transcription Kit (Life Technologies) and appropriate
miRNA specific hairpin RT primer according to the manufac-
turer’s instructions (assay IDs are listed in Supplementary
Material, Table S8). Subsequently, miRNAs were amplified using
Small RNA TaqMan assays and TaqMan Gene Expression
Master Mix on a Step-One Real-Time PCR instrument (all Life
Technologies). For absolute quantification, sample miRNA
quantities were compared to a 10 fold dilution series of syn-
thetic miRNA oligonucleotides (IDT) spiked-in at the RT stage.
Typical standard curves for all miRNAs are shown in
Supplementary Material, Figure S5. This technique enables the
comparison of measurements between experiments, and also
allows for direct comparison between different miRNA assays.
When appropriate, relative quantification was performed using
the Pfaffl equation (imputing PCR efficiency values determined
empirically by amplification curve analysis using LinRegPCR)
(77,78). Sample quantities were normalised to cel-miR-39 levels
in the case of biofluids (34), and to miR-16 levels for tissue sam-
ples. To obtain serummiRNA concentrations (copy numbers per
millilitre), the ratio of input volume used for extraction and
RNA resuspension volume was calculated and measured
miRNA copy numbers scaled accordingly.
RT-qPCR
RNA was extracted from cells or tissue using TRIzol reagent and
reversed transcribed using the High-Capacity cDNA Reverse
Transcription Kit (both Life Technologies) as according to man-
ufacturer’s instructions. Primer and probes used for qPCR were
obtained from IDT or Life Technologies and sequences/assay
IDs are shown in Supplementary Material, Table S9.
Cell culture
C2C12 cells were maintained in growth media; Dulbecco’s
Modified Eagle’s Media (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotics/antimycotics (all Life
Technologies) and cultured at 37˚C with 5% CO2. C2C12 myo-
blasts were differentiated in DMEM containing 2% horse serum
(HS) for 4-9 days to form multinucleated myotubes. Human pri-
mary myoblasts (a kind gift from Helene Fischer (Karolinska
Institutet, Stockholm, Sweden)) were obtained from a healthy,
25-year-old, Caucasian male donor with good physical fitness.
Cells were cultured in DMEM-F12 (20% FBS, 1% antibiotics/anti-
mycotics) until 80% confluency. For induction of differentia-
tion, serum concentrations were initially lowered to 2% HS and
then increased after 3 days to 5% HS.
To collect conditioned media for RNA extraction, cells
were cultured in differentiation media for 48–72 h. After col-
lection, media was spun at 2,000 g for 10min at 4˚C and
subsequently filtered (0.22 lm) to remove cellular debris and
apoptotic bodies. To block exosome secretion, C2C12 muscle
cells were differentiated for 4 days and then treated for 48h
with GW4869 (Sigma-Aldrich, Dorset, UK) at a final concentra-
tion of 10 lM. Subsequently, extracellular vesicles were iso-
lated from the supernatant as described below. To chemically
induce apoptosis, cells were differentiated for 6 days and
then treated with 1 lM Staurosporine (Abcam, Cambridge, UK)
for 24 h. Cell viability was determined by MTS assay using the
CellTiter 96 AQueous One Solution Cell Proliferation Assay kit
(Promega, Southampton, UK).
Extracellular vesicle isolation
Extracellular vesicles (EVs) were isolated by either a combina-
torial approach of ultrafiltration and size-exclusion chro-
matography (UF-SEC) as described previously (57) or by
ultracentrifugation (UC). To isolate EVs from conditioned media,
cells were cultured in pre-spun media which contains serum
that has been pre-cleared of serum EVs (120,000 g, 70min). For
EV isolation by UF-SEC, conditioned media or serum was spun
at 2,000 g for 10min at 4˚C, filtered (0.22 lm) and subsequently
concentrated on a 10kDa cut-off Amicon Ultra-15 spin filter
(EMD Millipore, Watford, UK) at 3,500 g for 15min. Filters were
washed with PBS and the combined retentate was loaded onto a
HiPrep 16/60 Sephacryl S-400 (GE Healthcare, Pollards Wood,
UK) connected to an €AKTA prime (GE Healthcare) equipped with
a UV flow cell where fixed volume (2ml) fractions were col-
lected. Based on UV 280nm absorbance values (indicative of pro-
tein content), the collected fractions were grouped into 4-6 new
fractions. These fractions were pooled and re-concentrated us-
ing the 10 kDa cut-off filter (EMD Millipore) to a final volume of
200 ll. For EV isolation by UC, conditioned media was prepared
as described above and ultracentrifuged twice at 120,000 g for
70min and pellets were washed with phosphate-buffered saline
(PBS) between the two spins to minimise protein contamina-
tion. EV-pellets were re-suspended in a final volume of 50 ll in
PBS.
Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) was performed to deter-
mine particle counts and size with a NanoSight NS500 instru-
ment (Malvern Instruments Ltd, Malvern, UK) equipped with
the NTA 2.3 analytical software. Samples were diluted in PBS to
achieve a particle count of between 2  108 per ml and 2  109
per ml. Three 30s videos for each sample were recorded using
the script control function and measurements were then ana-
lysed using the batch process facility.
Immunofluorescence and trypan blue exclusion assay
To detect apoptosis, the FITC Annexin V Apoptosis Detection
Kit I (BD Pharmingen, Plymouth, UK) was used for fluorescence
staining with minor alterations to the manufacturer’s protocol.
In brief, cells were washed in 1x Binding Buffer and then stained
for 30min with propidium iodide, Annexin V-FITC (both 1:30)
and Hoechst (1:1000).
Trypan Blue was also used to assess cell viability by dye
exclusion assay. In brief, cells were incubated with 0.4%
Trypan Blue Solution (Sigma-Aldrich) for 2min and analysed for
dye uptake with the EVOS FL cell imaging system (Life
Technologies).
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Western blot
Samples were diluted 1:1 with 2 Laemmli sample buffer (Bio-
Rad, Hemel Hempstead, UK) containing 5% b-mercaptoethanol
and heated at 100 C for 10min. Western blot was performed us-
ing the following primary antibodies; anti-CD9 (ab92726), anti-
ALIX (PDC6IP) (ab117600) and anti-TSG101 (ab30871); all at 1:1,000
dilution (all Abcam). For detection, secondary antibodies conju-
gated to infrared dyes (anti-mouse IgG IRDye800 (926-32210)
for detection of ALIX (1:10,000); anti-rabbit IgG 680RD (926-68071)
for detecting CD9 and TSG101 (1:10,000)) and LI-COR Odyssey CLx
infrared imaging systemwere used (all LI-COR, Cambridge, UK).
ELISA
CD63 ELISA (ABIN1572929, Antibodies Online, Aachen, Germany)
was performed according to manufacturer’s instructions. Each
fraction was diluted to fall within the linear range of the assay.
Sample concentrations were extrapolated with GraphPad Prism 5
(GraphPad Software Inc, La Jolla, CA) using fourth-order polyno-
mial data fit of the standard curves. CD63 quantities were nor-
malised to total protein amounts as determined by micro BCA
assay (Thermo Fisher Scientific, Bicester, UK).
Statistical analysis
Statistical analyses were carried out utilising GraphPad Prism 5.
Comparisons between two groups were tested using a two-
sided t-test. One-way analysis of variance (ANOVA) and
Bonferroni correction post hoc test were performed for compari-
sons of one variable in more than two groups. If the influence of
two independent variables was tested, two-way ANOVA with
Bonferroni post testing was applied. Differences were consid-
ered significant at P-values less than 0.05. Pearson correlation
analysis was performed with GraphPad Prism 5.
Supplementary Material
Supplementary Material is available at HMG online.
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